The Stop Tuberculosis Partnership
No hay miniatura disponible
Fecha
Autores
Título de la revista
ISSN de la revista
Título del volumen
Editor
Washington, DC: World Bank
Resumen
Descripción
The stop Tuberculosis (TB) partnership
is a network of international organizations, countries,
governmental and nongovernmental organizations, public and
private sector donors, and individuals dedicated to the
elimination of tuberculosis as a public health problem. The
partnership is a loose coalition of partners working to
elevate action on tuberculosis, one of the leading causes of
death from infectious disease, on the global agenda. The
stop TB partnership was formally established in 2001, as it
became clear to the international community that the initial
targets set for TB control in 1991.The specific objectives
for which the partnership has been accountable have evolved
somewhat since 2001, and have recently been stated most
clearly in the global plan to stop TB, 2006-2015. Since the
present Global Program Review (GPR) covers the period from
the initiation of the program to the present, it has
reviewed the achievements of the stop TB partnership against
four objectives which have been synthesized from core
partnership documents going back to 2001, namely: 1) to
expand the Directly Observed Treatment Short-Course (DOTS)
strategy so that all people have access to effective
diagnosis and treatment; 2) to develop and scale-up
effective responses to the emerging challenges of drug
resistance and HIV-related TB; 3) to improve and expand
tools available for TB diagnosis, treatment and prevention;
and 4) to strengthen the overall global partnership to stop
TB so that proven TB-control strategies are effectively applied.
Palabras clave
ACQUIRED IMMUNODEFICIENCY SYNDROME, ACQUISITION, AIDS VACCINE, ANTI-TB DRUGS, ANTIGENS, ANTIRETROVIRAL TREATMENT, ARV, BACTERIOLOGY, BOARD MEETING, BOARD MEMBER, BURDEN OF DISEASE, CAUSES OF DEATH, CHARTER, CHEMOTHERAPY, CLINICAL TRIALS, COLLECTIVE, COLLECTIVE ACTION, COMMUNICABLE DISEASES, COMPANY, CONFIRMED SPUTUM SMEAR, CONSOLIDATION, CONTROL PROGRAMS, CORPORATE CONSTITUENCY, CORPORATION, CORPORATIONS, DEVELOPMENT GRANT FACILITY, DGF, DIAGNOSIS, DIAGNOSTICS, DISABILITY, DISEASE, DISEASE CONTROL, DNA, DRUG COMPANIES, DRUG RESISTANCE, ENDEMIC COUNTRIES, EPIDEMIC, EPIDEMIOLOGICAL ASPECTS, EPIDEMIOLOGY, HEALTH CARE, HEALTH SERVICES, HEALTH STATUS, HEALTH STATUS OF POOR, HIB, HIV, HIV/AIDS, IAVI, IMMUNODEFICIENCY, INDIVIDUALS, INFECTION, INFECTION CONTROL, INFECTIOUS PATIENTS, INTERESTED PARTIES, INTERNATIONAL AIDS VACCINE INITIATIVE, ISONIAZID, LEPROSY, LIMITED, LUNG DISEASE, LUNGS, MALARIA, MANAGERS, MEMBER STATES, MORTALITY, NON-GOVERNMENTAL ORGANIZATION, NON-GOVERNMENTAL ORGANIZATIONS, PARTNERSHIP, PARTNERSHIP FRAMEWORK, PATIENTS, PEDIATRIC TUBERCULOSIS, PERSONS, PREVALENCE, PROPRIETARY, PUBLIC HEALTH, PULMONARY TUBERCULOSIS, RESISTANT TUBERCULOSIS, SECOND-LINE DRUGS, SHORT COURSE CHEMOTHERAPY, SMEAR POSITIVE, SOCIETY, SPUTUM SMEAR, SPUTUM SMEAR MICROSCOPY, STAKEHOLDER, STAKEHOLDERS, SYMPTOMATIC PATIENTS SELF-REPORTING, SYMPTOMS, TB, TB CONTROL, TREATMENT, TREATMENT REGIMEN, TROPICAL DISEASES, TUBERCULOSIS, TUBERCULOSIS CONTROL, TUBERCULOSIS CONTROL STRATEGY, TUBERCULOSIS EPIDEMIOLOGY, TUBERCULOSIS PREVENTION, UNION, VACCINE, VACCINE DEVELOPMENT, VACCINE RESEARCH, VACCINES, VISION